We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Atrial Flow Regulator Helps Manage Heart Failure

By HospiMedica International staff writers
Posted on 16 Sep 2019
A next generation implantable shunt device treats heart failure (HF) or pulmonary hypertension (PH) symptoms by decompressing abnormal intra-atrial pressure.

The Occlutech (Schaffhausen, Switzerland) atrial flow regulator (AFR) HF Device is a double-disc shaped shunt placed in the septum between the left and right atriums, via a minimally invasive balloon atrial septostomy (BAS) procedure, in order to create a restrictive atrial septal opening. Made of nickel-titanium (Nitinol), the AFR is intended to maintain a permanent interatrial fenestration of varying diameters (6-10 mm) secured by two discs. Depending on the indication (HF or PH), the shunt allows for the controlled flow of blood between the atria of the heart.

Image: A novel blood flow regulator decompresses the heart (Photo courtesy of Occlutech).
Image: A novel blood flow regulator decompresses the heart (Photo courtesy of Occlutech).

By maintaining the predetermined diameter shunt open in the intra-atrial septum, cardiac pressure is substantially reduced, resulting in a decompression of the heart chambers which leads to reduced HF and PH symptoms, and as a result to an improved exercise tolerance and to better quality of life (QOL). The AFR HF Device is manufactured in different sizes, allowing for a unique, patient-oriented, and individualized treatment. The Occlutech AFR Device has received the European Union CE mark of approval.

“With CE mark approval of the Occlutech AFR we are taking another big step towards becoming a multi-franchise congenital and structural heart disease therapy provider,” said Sabine Bois, Co-CEO of Occlutech. “The Occlutech AFR with its efficacy, versatility, convenience, and safety has true potential to revolutionize the way heart failure patients are treated.”

Unlike systemic blood pressure, pulmonary blood pressure reflects the pressure the heart exerts to pump blood from the right ventricle, which receives the oxygen-depleted blood, into the pulmonary arteries, and on to the left atrium. Normal pulmonary artery pressure is 8-20 mm Hg at rest (much lower than systemic blood pressure); if the pressure in the pulmonary artery is greater than 25 mm Hg at rest or 30 mmHg during physical activity, it is abnormally high and is called PH.

Related Links:
Occlutech


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Vertebral Body Replacement System
Hydrolift
New
Blanket Warming Cabinet
EC250

Latest Critical Care News

AI-Powered Wearable Device Revolutionizes Gut Health Diagnosis

Innovative Ventricular Assist Device Provides Long-Term Support for Advanced Heart Failure Patients

Novel Algorithms Predict Cardiovascular Outcomes at Point-Of-Care Using ECG Data